
Inflammx Therapeutics, a Tampa-based biotech startup, develops oral clinical-stage compounds.
InflammX Therapeutics, a Tampa-based biotech startup founded in 2020, focuses on developing novel upstream technologies to treat diseases where the inflammasome (NLRP3) pathway of inflammation is dysregulated and autoinflammatory. Their lead product, Xiflam™, is a once-daily orally administered small molecule targeting the pathologically open Connexin43 (Cx43) hemichannel, which is responsible for inflammasome-mediated autoinflammation in several disease states.
InflammX Therapeutics has made significant strides in the clinical development of Xiflam™, positioning it as a promising therapeutic solution for conditions involving chronic inflammation. By addressing the underlying mechanisms of autoinflammation, InflammX aims to provide effective treatments for a range of diseases, potentially improving patient outcomes and quality of life.

Inflammasome Therapeutics
inflam.com

Immvention Therapeutix

Inflammatix
inflammatix.com

Forward Therapeutics
forward-tx.com

Exalys Therapeutics
Promakhos Therapeutics
promakhos.com

Invea Therapeutics
inveatx.com

IpiNovyx Bio

HCW Biologics
hcwbiologics.com

Halia Therapeutics

Inflammatory Response Research
irrinc.net

Lapix Therapeutics
lapix.com

Innox
innoxpharma.com

Resolvyx Pharmaceuticals

Olatec Therapeutics
olatec.com
Companies similar to InflammX Therapeutics include Inflammasome Therapeutics, Immvention Therapeutix, Inflammatix and Forward Therapeutics.
InflammX Therapeutics was founded in 2020.
InflammX Therapeutics' headquarters is located in Tampa, FL, US.
InflammX Therapeutics' most recent funding round was for $8.4M (USD) in November 2021.
As of Nov 19, 2021, InflammX Therapeutics has raised a total of $8.4M (USD).
InflammX Therapeutics has 6 employees as of Feb 5, 2024.